Benefits of the next comparative study have been described by Flinn et al. This is a stage III randomized Intergroup trial comparing FC regimen as opposed to FAMP by itself in 278 sufferers acquiring their initial chemotherapy program for B-CLL. Dosages of FC schedule have been the same as the https://lukassxcgj.humor-blog.com/29310475/the-best-side-of-srt1720-hydrochloride